NasdaqGM:CRVSBiotechs
Does Corvus Pharmaceuticals’ (CRVS) Soquelitinib Focus Clarify Its Core Strategy or Concentration Risk?
Corvus Pharmaceuticals recently presented at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, highlighting updated clinical and development plans for its lead candidate soquelitinib across multiple indications.
The company emphasized strong early atopic dermatitis data for soquelitinib and outlined an international phase II trial and a phase III lymphoma interim analysis, underscoring how this single asset anchors its clinical pipeline.
We will now examine how the emerging...